Mary Beth Dorr
About Mary Beth Dorr
Mary Beth Dorr, Vice President, Clinical Science
Mary Beth Dorr serves as the Vice President of Clinical Science. With an extensive career in the pharmaceutical industry, she has spearheaded various drug development initiatives, focusing primarily on anti-infective products. Her tenure in this role reflects a commitment to advancing clinical science and product development.
Education and Expertise of Mary Beth Dorr
Mary Beth Dorr holds a Ph.D. in Pharmaceutics with a concentration on pharmacokinetics and drug metabolism from the University of North Carolina at Chapel Hill. She also earned a B.S. in Pharmacy from the University of the Sciences in Philadelphia. Following her academic achievements, Dorr completed a clinical pharmacy residency at the Veteran's Administration Hospital in Philadelphia, establishing a strong foundation in clinical pharmacology.
Professional Background of Mary Beth Dorr
Mary Beth Dorr's professional experience spans multiple prestigious pharmaceutical companies. She has held key positions such as Product Development Team Leader and Clinical Lead for Infectious Diseases at Merck, where she led clinical development for ZINPLAVA (bezlotoxumab) and managed the teams for DIFICID (fidaxomicin) and CUBICIN (daptomycin). At Wyeth, she served as Senior Director of Global Medical Affairs and Pandemic Preparedness Advisor. Her earlier roles include a senior research scientist at Rhône-Poulenc Rorer, managing clinical pharmacokinetic development for ZAGAM (sparfloxacin) and conducting trials for SYNERCID (quinupristin/dalfopristin). At Vicuron Pharmaceuticals, she was the development team project manager for dalbavancin.
Achievements in Drug Development by Mary Beth Dorr
Mary Beth Dorr has made significant contributions to drug development, particularly in the field of anti-infective products. She led the clinical development of ZINPLAVA (bezlotoxumab) at Merck and managed the development teams for DIFICID (fidaxomicin) and CUBICIN (daptomycin). At Rhône-Poulenc Rorer, she was responsible for the clinical pharmacokinetic development of ZAGAM (sparfloxacin) and managed several phase 1 and phase 3 trials. Her work in drug development is backed by over 30 years of experience, making her a key figure in the pharmaceutical industry.
Experience of Mary Beth Dorr in Clinical Pharmacokinetics
Mary Beth Dorr has a robust background in clinical pharmacokinetics, starting from her work at Rhône-Poulenc Rorer and Parke-Davis, where she designed and implemented preclinical and clinical pharmacokinetic research for quinolone antibiotics. Throughout her career, she has consistently focused on developing anti-infective drugs, culminating in her leadership roles at major pharmaceutical firms like Merck and Wyeth. Her extensive experience includes managing phase 1 and phase 3 clinical trials, emphasizing her expertise in this critical aspect of drug development.